EPIX - ESSA Pharma Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.2000
+0.4000 (+22.22%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.8000
Open1.7800
Bid0.0000 x 900
Ask0.0000 x 1300
Day's Range1.6300 - 2.3200
52 Week Range1.4100 - 4.5000
Volume431,555
Avg. Volume18,809
Market Cap33.756M
Beta (3Y Monthly)1.85
PE Ratio (TTM)N/A
EPS (TTM)-1.7470
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Benzinga

    10 Biopharmaceutical Companies Trying To Cure Cancer

    Cancer. Research shows nearly every sixth death in the world is due to the disease, making it the second leading cause of death behind cardiovascular diseases. The global pharmaceutical industry is estimated ...

  • CNW Group

    ESSA Pharma Announces $36 Million Public Offering of Common Stock and Concurrent Private Placement

    TSXV: EPI) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce a public offering of equity securities of the Company in Canada and a concurrent private placement of equity securities in the United States (the "Offering"). The Offering is being led by Soleus Capital and includes RA Capital Management as a new investor.

  • CNW Group

    ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2019

    ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2019

  • CNW Group

    ESSA Announces that the Scheme of Arrangement with Realm Therapeutics has become Effective

    TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that, further to the announcement made on July 30, 2019 , the scheme of arrangement under Part 26 of the U.K. Companies Act 2006 (the "Scheme") has become effective and ESSA has acquired all of the issued and outstanding shares of Realm Therapeutics plc ("Realm"). "The addition of Realm's cash to our balance sheet will allow us to conduct the Phase I trial of EPI-7386," commented Dr. David R. Parkinson , Chief Executive Officer of ESSA.

  • PR Newswire

    ESSA Announces Court Sanction of the Scheme of Arrangement with Realm Therapeutics

    TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that, further to the announcement made on July 8, 2019, the High Court of Justice in England and Wales has today sanctioned the scheme of arrangement under Part 26 of the U.K. Companies Act 2006 (the "Scheme"), pursuant to which ESSA will acquire all of the issued and outstanding shares of Realm Therapeutics plc ("Realm"). It is intended that the order of the court sanctioning the Scheme will be delivered to the Registrar of Companies in England and Wales on July 31, 2019. Unless otherwise defined herein, capitalized terms and expressions used in this announcement shall have the meanings given to them in the scheme document published by Realm on May 29, 2019.

  • CNW Group

    ESSA Expands Leadership Team by appointing Alessandra Cesano as Chief Medical Officer

    TSX-V: EPI), a pharmaceutical company focused on the developing novel therapies for the treatment of prostate cancer, announced today the appointment of Dr. Alessandra Cesano , M.D., PhD as Chief Medical Officer ("CMO").  With over 25 years of drug development, regulatory and medical affairs activities, Dr. Cesano will provide leadership in advancing the Company's lead clinical candidate, EPI-7386 into Phase 1 clinical testing. "Dr. Cesano is an accomplished drug development executive with an extensive and successful track record of leading drug candidates though development, approval and commercial launch.

  • PR Newswire

    ESSA Provides Update on Court Hearing

    TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announces that the hearing at the High Court of Justice in England and Wales (the "Court") in respect of the proposed scheme of arrangement under Part 26 of the U.K. Companies Act 2006 (the "Scheme"), pursuant to which ESSA will acquire all of the issued and outstanding shares of Realm Therapeutics plc ("Realm"), took place today in London. The Court reserved judgment and, as such, the Court has not yet rendered its decision upon the sanctioning of the Scheme. As a consequence of the reserved judgment, there is likely to be an update to the expected timetable of principal events for the implementation of the Scheme from that set out in the announcement made by the Company on June 26, 2019.

  • PR Newswire

    ESSA Provides an Update to the Acquisition of Realm Therapeutics

    TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer provides an update, further to the announcement made on May 16, 2019 announcing the acquisition of Realm Therapeutics plc ("Realm") by ESSA pursuant to a scheme of arrangement under Part 26 of the U.K. Companies Act 2006 (the "Scheme").  The Court Meeting and General Meeting in relation to the Scheme were each held by Realm on June 24, 2019 in London, United Kingdom and all resolutions proposed by Realm at such meetings were approved. The Court Hearing to sanction the Scheme has been postponed to July 8, 2019, later than expected, due to a Realm shareholder opposing the Scheme.  ESSA expects that the Scheme will become effective (and the acquisition will complete) on July 10, 2019, if the Court sanctions the Scheme on July 8, 2019.

  • CNW Group

    ESSA Pharma Inc. Reports Results of Annual General Meeting of Shareholders

    HOUSTON, TX AND VANCOUVER , June 25, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its annual general meeting of shareholders of the Company (the "Shareholders") held on June 25, 2019 in Vancouver, British Columbia , Canada (the "Meeting"). At the Meeting, the Shareholders set the number of directors at seven and re-elected to the board of directors (the "Board"), by ordinary resolution passed by ballot vote, David R. Parkinson , Richard M. Glickman , Raymond Andersen , Gary Sollis , Franklin M. Berger , Scott Requadt and Otello Stampacchia to serve in office until the next annual meeting of Shareholders or until their successors are duly elected or appointed.

  • CNW Group

    ESSA Pharma to Hold Annual Shareholders' Meeting and Announces Three Realm-Nominated Directors

    TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer reminds investors that ESSA will hold its Annual General Meeting of Shareholders on Tuesday, June 25, 2019 at 2:00 PT , at the offices of Blake, Cassels & Graydon LLP at Suite 2600, 595 Burrard Street, Vancouver British Columbia , Canada. As announced May 16, 2019 , ESSA reached an agreement for ESSA to acquire Realm Therapeutics plc ("Realm"), with an expected completion by mid-year 2019, subject to customary closing conditions including approval of Realm shareholders (the "Acquisition").  Upon the close of the Acquisition, it is expected that ESSA's Board of Directors will be increased to nine members and that one current director of the Company will resign. ESSA is pleased to announce the three candidates nominated by the Realm Board of Directors.

  • What Makes ESSA Pharma (EPIX) a New Buy Stock
    Zacks

    What Makes ESSA Pharma (EPIX) a New Buy Stock

    ESSA Pharma (EPIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

  • GlobeNewswire

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Realm Therapeutics plc to ESSA Pharma Inc., LLC is Fair to Shareholders

    NEW YORK, May 20, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Realm Therapeutics plc (“Realm” or.

  • PR Newswire

    Agreement Reached for ESSA Pharma to Acquire Realm Therapeutics

    Acquisition Expected to be Completed by Mid-Year 2019 VANCOUVER and   HOUSTON , May 16, 2019 /PRNewswire/ - ESSA Pharma Inc. (" ESSA " or "the Company ") (NASDAQ: EPIX; TSX-V: EPI) ...

  • CNW Group

    ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2019

    ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2019